Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

NeuroPace Q3 2026 Results: Net Loss of $3.3M, Loss Narrows

NeuroPace reported a decrease in total assets from $105.6 million at the end of 2025 to $94.8 million as of September 30, 2026, primarily driven by a reduction in cash and short-term investments. The company maintains a significant accumulated deficit of $568.6 million and expects to lose its emerging growth company status on December 31, 2026.

Watch the NeuroPace Inc earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue23.123.4
Gross profit19.519.2
Net income-3.3-3.5
EPS (diluted, $ a share)$-0.10$-0.11

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-1.1%
Gross margin84.3%
Operating margin-9.0%
Source

10-Q filed with the SEC, NASDAQ: NPCE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

NeuroPace Inc: key numbers

Share price
$7.97Close, Nov 16
Market cap
$275M
Shares outstanding
34.45MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from NeuroPace Inc

All →
4:09 PM ET 8-K
Financial Results

NeuroPace Financial Results

NeuroPace reported Q3 2026 total revenue of $23.1 million, missing internal expectations due to commercial execution issues and field organization disruption. The company revised its full-year 2026 revenue guidance downward to $91-$92 million while advancing its innovation pipeline, including an FDA submission for NeuroPace Remote Care.

Term
Q3 2026

“Third-quarter revenue was below our expectations, and we have taken and are taking action to improve commercial execution and return the business to historical growth rates. The shortfall was concentrated in several of our largest accounts and reflected isolated account-level issues and changes to our field organization that created more disruption than anticipated.”

Joel Becker, President and Chief Executive Officer of NeuroPace

“Our innovation pipeline represents one of the most significant opportunities ahead for NeuroPace, combining potential indication expansion with capabilities that can make RNS therapy more accessible, efficient and personalized.”

Joel Becker, President and Chief Executive Officer of NeuroPace

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.